TM5614

TM5614 is a novel, orally active plasminogen activator inhibitor-1 (PAI-1) inhibitor. It works by inhibiting PAI-1 activity, which consequently leads to the downregulation of hepatic PCSK9 transcription, resulting in decreased plasma levels of PCSK9. This reduction in PCSK9 levels lowers the catabolism of LDL receptors, allowing more LDL-C to be cleared from circulation. PAI-1 is a marker associated with obesity, type 2 diabetes, and metabolic syndrome, making its inhibition a target for treating these conditions. TM5614 has shown promising results and a favorable safety profile in various clinical trials for indications including advanced melanoma, chronic myeloid leukemia (CML), and cutaneous angiosarcoma.

Other names

PAI-1 inhibitor RS5614PAI1 inhibitor RS5614PAI 1 inhibitor RS5614